Mid
A
ALNYAI Stock Diagnostic Report
Alnylam sees promising early-stage data for Huntington's asset brezosiran
알나일람이 헌팅턴병 치료제 브레조시란의 초기 임상에서 긍정적인 데이터를 확인해 주가에 긍정적입니다.
View Source Article ↗AI CATALYST SCORE68 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time